Cannara Biotech Inc.
LOVFFOTCHealthcare● Active
$1.20
+$0.00(+0.16%)
Market Cap$118736142
P/E Ratio—
52W High$1.47
52W Low$0.81222
Cannara Biotech Inc. (LOVFF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LOVFF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 14, 2026EPS Actual
$0.01
Est. $0.04 · -60.0%
Revenue
$0.02B
Est. $0.02B · -14.4%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 14, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
LOVFF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | Apr 14, 2026 | $0.04 | — | — | — | $0.02B | — |
| ▼ Q2 FY2026 | Apr 14, 2026 | $0.04 | $0.01 | -60.0% | $0.02B | $0.02B | -14.4% |
| — Q1 FY2026 | Jan 26, 2026 | — | $0.01 | — | $0.02B | $0.02B | -0.2% |
| — Q4 FY2025 | Nov 24, 2025 | — | $0.03 | — | $0.02B | — | — |
| — Q2 FY2025 | Apr 28, 2025 | — | $0.03 | — | $0.02B | — | — |
| — Q2 FY2025 | Apr 25, 2025 | — | $0.02 | — | $0.02B | — | — |
| — Q1 FY2025 | Jan 27, 2025 | — | $0.02 | — | $0.02B | — | — |
| — Q3 FY2024 | Aug 31, 2024 | — | $0.05 | — | $0.02B | — | — |
Q2 FY2026
Apr 14, 2026
EPS Actual
—
EPS Est.
$0.04
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 14, 2026Miss
EPS Actual
$0.01
EPS Est.
$0.04
EPS Surpr.
-60.0%
Revenue
$0.02B
Q1 FY2026
Jan 26, 2026
EPS Actual
$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q4 FY2025
Nov 24, 2025
EPS Actual
$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q2 FY2025
Apr 28, 2025
EPS Actual
$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q2 FY2025
Apr 25, 2025
EPS Actual
$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q1 FY2025
Jan 27, 2025
EPS Actual
$0.02
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Q3 FY2024
Aug 31, 2024
EPS Actual
$0.05
EPS Est.
—
EPS Surpr.
—
Revenue
$0.02B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q2 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q1 FY2027 | $0.00 | $0.00 | $0.00 | 0 |
| Q4 FY2026 | $0.00 | $0.00 | $0.00 | 0 |
| Q3 FY2026 | $0.04 | $0.04 | $0.04 | 1 |
| Q2 FY2026 | $0.05 | $0.05 | $0.05 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 2 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2026 | $0.0B | $0.0B | $0.0B | 3 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | Apr 14, 2026 | -60.0% | $1.44 | $1.39 | -3.47% |
| — Q1 FY2026 | Jan 26, 2026 | — | $1.44 | $1.39 | -3.47% |
| — Q4 FY2025 | Nov 24, 2025 | — | $1.21 | $1.30 | +7.44% |
| — Q2 FY2025 | Apr 28, 2025 | — | $1.01 | $1.01 | +0.00% |
| — Q2 FY2025 | Apr 25, 2025 | — | $0.99 | $1.01 | +2.02% |
| — Q1 FY2025 | Jan 27, 2025 | — | $0.62 | $0.66 | +6.45% |
| — Q3 FY2024 | Aug 31, 2024 | — | $0.54 | $0.58 | +7.97% |
| — Q3 FY2024 | Jul 23, 2024 | — | No price data | $0.44 | — |
Q2 FY2026-3.47%
Report Date
Apr 14, 2026
EPS Beat/Miss
-60.0%
Price Before
$1.44
Price After
$1.39
Q1 FY2026-3.47%
Report Date
Jan 26, 2026
EPS Beat/Miss
—
Price Before
$1.44
Price After
$1.39
Q4 FY2025+7.44%
Report Date
Nov 24, 2025
EPS Beat/Miss
—
Price Before
$1.21
Price After
$1.30
Q2 FY2025+0.00%
Report Date
Apr 28, 2025
EPS Beat/Miss
—
Price Before
$1.01
Price After
$1.01
Q2 FY2025+2.02%
Report Date
Apr 25, 2025
EPS Beat/Miss
—
Price Before
$0.99
Price After
$1.01
Q1 FY2025+6.45%
Report Date
Jan 27, 2025
EPS Beat/Miss
—
Price Before
$0.62
Price After
$0.66
Q3 FY2024+7.97%
Report Date
Aug 31, 2024
EPS Beat/Miss
—
Price Before
$0.54
Price After
$0.58
Q3 FY2024—
Report Date
Jul 23, 2024
EPS Beat/Miss
—
Price Before
—
Price After
$0.44
Avg Miss Reaction-3.47%
Beat Rate0 / 8 quarters
Largest Move+7.97% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LOVFF ends December
Cannara Biotech Inc. (LOVFF) most recently reported earnings on April 14, 2026 for Q2 FY2026, posting EPS of $0.01 — missing the analyst consensus of $0.04 by -60.0%. The next LOVFF earnings date is expected around September 1, 2026.
Each quarter, investors track LOVFF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LOVFF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LOVFF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LOVFF earnings · 5 questionsCannara Biotech Inc.'s next earnings report is expected around September 1, 2026. LOVFF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LOVFF historically reports after market close (AMC).
LOVFF earnings datewhen is LOVFF earningsLOVFF next earnings datewhen does LOVFF report earningsLOVFF earnings calendar
▸ Source: FMP · Cannara Biotech Inc. SEC filings · US GAAP · Cannara Biotech Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026